Dataset Information


Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond.

ABSTRACT: Objectives:Tofacitinib is an oral Janus kinase inhibitor for treatment of psoriatic arthritis (PsA). Patient-reported outcomes (PROs) were evaluated in patients with PsA with inadequate responses to tumour necrosis factor inhibitors (TNFi-IR) in a 6-month, phase III randomised controlled trial (OPAL Beyond [NCT01882439]). Methods:Patients (N=394) received tofacitinib 5 or 10?mg twice daily or placebo (advancing to tofacitinib 5 or 10?mg twice daily at month 3). Least squares mean changes from baseline and percentages of patients reporting improvements ?minimum clinically important differences and scores ?normative values were determined in Patient Global Assessment of disease activity (PtGA), Pain, Patient Global Joint and Skin Assessment (PGJS), Short Form-36 Health Survey version 2 (SF-36v2), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue), EuroQol 5-Dimensions-3-level (EQ-5D-3L), EQ-VAS and Ankylosing Spondylitis Quality of Life (ASQoL). Nominal p values are without multiple comparison adjustments. Results:At month 3, PtGA, Pain, PGJS, SF-36v2 Physical Component Summary (PCS), physical functioning (PF), bodily pain (BP), vitality and social functioning (SF) domains, FACIT-Fatigue Total score, EQ-5D-3L pain/discomfort, EQ-VAS and ASQoL scores exceeded placebo with both tofacitinib doses (role physical [RP] with 10?mg twice daily only; p?0.05). Patients reporting improvements ?MCID (%) in PtGA, PGJS, Pain, ASQoL and SF-36v2 PCS, PF, RP, BP, SF (both tofacitinib doses) exceeded placebo (p?0.05). Conclusion:TNFi-IR patients with PsA receiving tofacitinib reported statistically and clinically meaningful improvements in PROs versus placebo over 3 months, which were maintained to month 6. Despite lower baseline scores, these improvements were similar to the csDMARD-IR TNFi-naive OPAL Broaden trial.


PROVIDER: S-EPMC6340607 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6340575 | BioStudies
2016-01-01 | S-EPMC5051508 | BioStudies
2015-01-01 | S-EPMC4632359 | BioStudies
2017-01-01 | S-EPMC5413813 | BioStudies
2020-01-01 | S-EPMC7425192 | BioStudies
2018-01-01 | S-EPMC5817244 | BioStudies
1000-01-01 | S-EPMC5558590 | BioStudies
2018-01-01 | S-EPMC6251851 | BioStudies
1000-01-01 | S-EPMC5881763 | BioStudies
2017-01-01 | S-EPMC5604362 | BioStudies